The global high mobility group protein B1 market is expected to grow at a significant CAGR during the forecast period. High mobility group box 1 (HMGB1) is a chromatin-associated protein that is not histone. It is crucial in the pathogenesis of hematopoietic malignancies. Furthermore, in leukaemia and multiple myeloma, this protein autophagy promotes chemotherapy resistance. The increasing prevalence of leukaemia globally is the one of the prominent factors, the demand for high mobility group protein B1 is increasing at rapid rate. It is estimated that, there are around 9,900 new leukaemia cases in the UK every year. Leukaemia is the 12th most common cancer in the UK, accounting for 3% of all new cancer cases (2016-2018). And, as per the National Cancer Institute, there are 60,650 new cases of Leukemia can be expected in 2022, thereby driving the demand for high mobility group protein B1. 

Impact of COVID-19 Pandemic on Global High Mobility Group Protein B1 Market

The COVID-19 pandemic had impacted the global high mobility group protein B1 market industry significantly owning to the lockdown in most of the nations to control the spread of the virus that leads to the less patients visits in hospitals. 

Segmental Outlook 

The global high mobility group protein B1 market is segmented based on type and application. Based on the type, the market segmented into dociparstat sodium, RBM-005, EV-007156. Based on the application, the market is sub-segmented into autoimmune disorders, chemotherapy effects, Cerebral Infarction, and cancer treatment. 

Global High Mobility Group Protein B1 Market Share by Application, 2021 (%)

The Cancer Treatment Segment Holds the Major Share in the Global High Mobility Group Protein B1 Market

Based on application, the cancer treatment segment held the significant share in the market. The segment is According to the National Cancer Institute (NCI), 1,806,590 new cancer cases diagnosed in the US. in 2021, with a mortality rate of 606,520 people. Furthermore, in 2018, there were 18.1 million new cancer cases and 9.5 million cancer-related deaths worldwide, with these numbers expected to rise to 29.5 million new cases and 16.4 million cancer-related deaths by 2040. As a result, rising cancer rates are driving up demand for HMGB1. In cancer therapy, HMGB1 has been observed to regulate multiple signalling pathways, including proliferation, apoptosis, inflammation, immunity, autophagy, genome stability, metastasis, and metabolism, to promote both cell survival and death.

Regional Outlooks

The global high mobility group protein B1 market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). 

Global High Mobility Group Protein B1 Market Growth, by Region 2022-2028

The Asia-Pacific Region Expected to Hold Considerable Share in the Global High Mobility Group Protein B1 Market

Geographically, Asia-Pacific region holds the major share and is anticipated to grow fastest during the forecast period in the high mobility group protein B1 market. Cassava Sciences, Inc. announced additional clinical data from a Phase 2b study with sumifilam in patients with Alzheimer's disease funded by the National Institutes of Health (NIH) in November 2020. Sumifilam lowers HMGB1 levels and improves measurements of the blood-brain barrier's integrity (BBB). To stay competitive in the market, market players are using a variety of strategies such as mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches to contribute significantly to market growth.

Market Players Outlook

The major companies serving the global high mobility group protein B1 market include Affibody AB, Cantex pharmaceuticals, Dicerna pharmaceuticals, Evec Inc., Ribomic Inc., and among others. These market players are focusing on adopting numerous growth strategies such as new product launches, mergers and acquisitions, partnership, business expansion and others in order to fulfil the growing market demands. 

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global high mobility group protein B1 market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.